These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35868334)

  • 21. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
    Riemsma R; Al M; Corro Ramos I; Deshpande SN; Armstrong N; Lee YC; Ryder S; Noake C; Krol M; Oppe M; Kleijnen J; Severens H
    Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liraglutide versus colesevelam for treating bile acid diarrhoea.
    Zhang F; Ge C
    Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1075. PubMed ID: 36370737
    [No Abstract]   [Full Text] [Related]  

  • 23. Liraglutide versus colesevelam for treating bile acid diarrhoea - Authors' reply.
    Kårhus ML; Knop FK
    Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1075-1076. PubMed ID: 36370738
    [No Abstract]   [Full Text] [Related]  

  • 24. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
    Armstrong MJ; Gaunt P; Aithal GP; Barton D; Hull D; Parker R; Hazlehurst JM; Guo K; ; Abouda G; Aldersley MA; Stocken D; Gough SC; Tomlinson JW; Brown RM; Hübscher SG; Newsome PN
    Lancet; 2016 Feb; 387(10019):679-690. PubMed ID: 26608256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
    Pratley RE; Nauck MA; Barnett AH; Feinglos MN; Ovalle F; Harman-Boehm I; Ye J; Scott R; Johnson S; Stewart M; Rosenstock J;
    Lancet Diabetes Endocrinol; 2014 Apr; 2(4):289-297. PubMed ID: 24703047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial.
    Vijayvargiya P; Camilleri M; Carlson P; Nair A; Nord SL; Ryks M; Rhoten D; Burton D; Busciglio I; Lueke A; Harmsen WS; Donato LJ
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2962-2970.e6. PubMed ID: 32088296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
    Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
    Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
    Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
    Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
    Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
    Seino Y; Rasmussen MF; Nishida T; Kaku K
    Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
    Neeland IJ; Marso SP; Ayers CR; Lewis B; Oslica R; Francis W; Rodder S; Pandey A; Joshi PH
    Lancet Diabetes Endocrinol; 2021 Sep; 9(9):595-605. PubMed ID: 34358471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
    Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
    Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of treatment with bile acid sequestrants on quality of life in patients with bile acid diarrhoea.
    Kumar A; Galbraith N; Al-Hassi HO; Jain M; Phipps O; Butterworth J; Steed H; McLaughlin J; Brookes MJ
    BMC Gastroenterol; 2022 Jul; 22(1):325. PubMed ID: 35778677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.